Dendritic cell-based glioma immunotherapy reviewed.

2003 AUG 20 - (NewsRx.com & NewsRx.net) -- A review of dendritic cell-based glioma immunotherapy has been published in a recent issue of the International Journal of Oncology.

According to a study from Japan, "Despite advances in radiation and chemotherapy along with surgical resectioning, the prognosis of patients with malignant glioma is poor. Among the new treatments currently being investigated for malignant glioma, immunotherapy is theoretically very attractive, since it offers the potential for high tumor-specific cytotoxicity."

"There are increasing reports demonstrating that systemic immunotherapy using dendritic cells is capable of inducing an antiglioma response," said Ryuya Yamanaka and colleagues at Niigata University. "Therefore, dendritic cell-based immunotherapy could be a new treatment modality for patients with glioma. In this review, we will discuss the implications of these findings for glioma therapy."

"A literature review of dendritic cell-based glioma immunotherapy was used to overview the dendritic cell in immunobiology, in the central nervous system and in tumor immunology, glioma-associated antigens, dendritic cell therapy in animal glioma model, dendritic cell therapy in clinical trials and future directions in dendritic cell therapy," stated Yamanaka and collaborators. "Dendritic cell-based ...